KA
DMTK

Kerrisdale Advisers’s DermTech, Inc. Common Stock DMTK Stock Holding History

Kerrisdale Advisers’s Portfolio DMTK Stock Details DMTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-50,000
Closed -$1.62M – 81
2020
Q4 		$1.62M Buy
+50,000
New +$709K 0.13% 59

Other funds holding DMTK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Kerrisdale Advisers's DMTK Position: Q1 2021 in Review

Kerrisdale Advisers sold out of DermTech, Inc. Common Stock (DMTK) in Q1 2021, closing a stake of 50,000 shares — an estimated $1.62M sold.

Kerrisdale Advisers first reported a position in DMTK in Q4 2020 and held it in 1 quarter. The position peaked at $1.62M in Q4 2020. 169 funds tracked by Wall St. Rank hold DMTK as of Q1 2021.

  • Kerrisdale Advisers reported no remaining DermTech, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Kerrisdale Advisers sold 50,000 DermTech, Inc. Common Stock shares in Q1 2021, an estimated $1.62M.
  • Kerrisdale Advisers first reported a position in DermTech, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Kerrisdale Advisers's DermTech, Inc. Common Stock position peaked at $1.62M in Q4 2020.
  • 169 funds tracked by Wall St. Rank held DermTech, Inc. Common Stock as of Q1 2021.

Based on Kerrisdale Advisers's 13F filing for Q1 2021, filed 17 May 2021.